NEW HAVEN, Conn., June 17, 2019 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical‑stage
biopharmaceutical company with a portfolio of innovative,
late‑stage product candidates targeting neurological diseases,
including rare disorders, today announced that it has commenced an
underwritten public offering of $300 million of its common
shares. All of the common shares to be sold in the offering will be
offered by Biohaven. In addition, Biohaven expects to grant
the underwriters a 30-day option to purchase up to an additional
$45 million of common shares at the
public offering price, less underwriting discounts and commissions.
The offering is subject to market and other conditions, and
there can be no assurance as to whether or when the offering may be
completed, or the actual size or terms of the offering.
Goldman Sachs & Co. LLC and Piper
Jaffray & Co. are acting as joint book-running managers
of the offering.
The offering is being made only by means of a prospectus.
When available, copies of the prospectus related to the offering
may be obtained from the offices of Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York,
NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316
or by emailing Prospectus-ny@ny.email.gs.com; or from
Piper Jaffray & Co., Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis,
MN 55402, or by telephone at (800) 747-3924, or by email
at prospectus@pjc.com.
The shares will be issued pursuant to an effective shelf
registration statement on Form S-3. Before investing in the
offering, interested parties should read the prospectus and related
prospectus supplement for this offering, the documents incorporated
by reference therein and the other documents Biohaven has filed
with the Securities and Exchange Commission. This press release
shall not constitute an offer to sell or a solicitation of an offer
to buy any of these securities, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the applicable securities laws of such state
or jurisdiction.
Contact
Dr. Vlad Coric
Chief Executive Officer
Biohaven Pharmaceutical Holding Company Ltd.
Phone: (203) 404-0410
Email: vlad.coric@biohavenpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohaven-announces-proposed-public-offering-of-common-shares-300869887.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.